Suppr
超能文献

无转移生存与生化复发前列腺癌无治疗生存：EMBARK 试验。

Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial.

机构信息

Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA.

Harvard Medical School, Boston, MA.

出版信息

J Clin Oncol. 2024 Aug 20;42(24):2849-2852. doi: 10.1200/JCO.24.00279. Epub 2024 May 16.

DOI:10.1200/JCO.24.00279

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11457111/

Abstract

What is most important to patients with BCR prostate cancer? Metastasis-free versus treatment-free survival.

摘要

对于患有 BCR 前列腺癌的患者来说，最重要的是什么？无转移生存与无治疗生存。

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial.

J Clin Oncol. 2024 Aug 20;42(24):2849-2852. doi: 10.1200/JCO.24.00279. Epub 2024 May 16.

2

Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database.

Cancer. 2014 Jan 15;120(2):197-204. doi: 10.1002/cncr.28423. Epub 2013 Oct 11.

3

Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.

Anticancer Res. 2017 Oct;37(10):5631-5637. doi: 10.21873/anticanres.11998.

4

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.

5

Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.

J Urol. 2021 Sep;206(3):623-629. doi: 10.1097/JU.0000000000001797. Epub 2021 May 18.

6

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.

7

Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer?

BJU Int. 2021 Jun;127(6):654-664. doi: 10.1111/bju.15236. Epub 2020 Sep 26.

8

Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.

Eur J Cancer. 2021 Nov;157:259-267. doi: 10.1016/j.ejca.2021.06.017. Epub 2021 Sep 15.

9

Predicting factors for progression to castration resistance prostate cancer after biochemical recurrence in patients with clinically localized prostate cancer who underwent radical prostatectomy.

Int J Clin Oncol. 2020 Sep;25(9):1704-1710. doi: 10.1007/s10147-020-01716-8. Epub 2020 Jun 4.

10

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.

Lancet Oncol. 2014 Oct;15(11):1263-8. doi: 10.1016/S1470-2045(14)70417-6. Epub 2014 Sep 18.

引用本文的文献

1

The role of radiotherapy in pelvic nodal recurrence following definitive treatment for prostate cancer.

Curr Opin Urol. 2025 Sep 1;35(5):574-582. doi: 10.1097/MOU.0000000000001322. Epub 2025 Jul 17.

2

PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging.

JAMA Netw Open. 2025 Jan 2;8(1):e2452971. doi: 10.1001/jamanetworkopen.2024.52971.

本文引用的文献

1

Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients.

Curr Opin Oncol. 2024 May 1;36(3):164-168. doi: 10.1097/CCO.0000000000001030. Epub 2024 Feb 23.

2

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.

N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974.

3

Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.

J Clin Oncol. 2022 Oct 10;40(29):3377-3382. doi: 10.1200/JCO.22.00644. Epub 2022 Aug 24.

4

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.

Clin Cancer Res. 2021 Dec 15;27(24):6687-6695. doi: 10.1158/1078-0432.CCR-21-2283. Epub 2021 Nov 10.

5

Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.

Circulation. 2021 Oct 19;144(16):1295-1307. doi: 10.1161/CIRCULATIONAHA.121.056810. Epub 2021 Aug 30.

6

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.

Eur Urol. 2021 Sep;80(3):275-279. doi: 10.1016/j.eururo.2021.05.016. Epub 2021 May 22.

7

Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.

J Urol. 2021 Sep;206(3):623-629. doi: 10.1097/JU.0000000000001797. Epub 2021 May 18.

8

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.

N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29.

9

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.

Lancet Oncol. 2019 Dec;20(12):1730-1739. doi: 10.1016/S1470-2045(19)30688-6. Epub 2019 Nov 11.

10

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.

J Clin Oncol. 2019 Dec 10;37(35):3350-3358. doi: 10.1200/JCO.19.00345. Epub 2019 Sep 9.